USE OF THE USDT FLOW IMMUNOSENSOR FOR QUANTITATION OF BENZOYLECGONINEIN URINE

The flow immunosensor works on a principle somewhat distinct from othe r immunoassay systems in that it performs a displacement immunoassay. Antibody-coated matrices are saturated with fluorescently labeled benz oylecgonine (BE), which is released and measured in the presence of BE -containing urine and measured downstream from the matrix. The same an tibody matrix can be used for many samples. A flow immunosensor instru ment, built by US Drug Testing, Inc., has recently received 'Premarket Notification' (510(K)) from the Food and Drug Administration (FDA) to screen urine for the presence of the cocaine metabolite BE. The perfo rmance of the flow immunosensor for screening BE in urine was validate d by comparison with results of a blind study using the Syva EMIT, the Abbott TDx and gas chromatography-mass spectroscopy (CC-MS). Potentia lly interfering drugs were also spiked into urine and evaluated using the flow immunosensor. While the FDA approval is for determining wheth er the BE concentration is above or below the 300 mu g/l cutoff recomm ended by the National Institute of Drug Abuse, we have also shown that the flow immunosensor can be adapted to produce quantitative determin ations of the amount of BE in the urine samples. The reliability of th e quantitation was confirmed by testing 100 urine samples containing u nknown amounts of BE using the flow immunosensor, CC-MS and the Abbott TDx system. Comparison of quantitative data obtained using the immuno sensor and CC-MS showed a 97% correlation, compared with a much lower value for data from the TDx and CC-MS.